Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential

MUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals at-risk for colon cancer. This trial provided a unique source of potentially effective and safe immunothe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Lohmueller, Jason J., Sato, Shuji, Popova, Lana, Chu, Isabel M., Tucker, Meghan A., Barberena, Roberto, Innocenti, Gregory M., Cudic, Mare, Ham, James D., Cheung, Wan Cheung, Polakiewicz, Roberto D., Finn, Olivera J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4992835/
https://ncbi.nlm.nih.gov/pubmed/27545199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep31740
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados